Association between spironolactone use and COVID-19 outcomes in population-scale claims data: a retrospective cohort study

Henry C. Cousins, Russ B. Altman
doi: https://doi.org/10.1101/2023.02.28.23286515

Article Information

doi 
https://doi.org/10.1101/2023.02.28.23286515
History 
  • March 2, 2023.
Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.

Author Information

  1. Henry C. Cousins1 and
  2. Russ B. Altman1,2,3,4,*
  1. 1Department of Biomedical Data Science, Stanford University School of Medicine, Stanford, CA, USA
  2. 2Department of Bioengineering, Stanford University, Stanford, CA, USA
  3. 3Department of Genetics, Stanford University School of Medicine, Stanford, CA, USA
  4. 4Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA
  1. ↵*Corresponding author:
    Russ B. Altman, M.D., Ph.D., 443 Via Ortega, MC 4245, Stanford, CA 94305, russ.altman{at}stanford.edu
Back to top
Posted March 02, 2023.
Download PDF

Supplementary Material

Data/Code
Email
Association between spironolactone use and COVID-19 outcomes in population-scale claims data: a retrospective cohort study
Henry C. Cousins, Russ B. Altman
medRxiv 2023.02.28.23286515; doi: https://doi.org/10.1101/2023.02.28.23286515
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area